| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/15/2013 | US20130210116 Composition and methods for the diagnosis and treatment of tumor |
| 08/15/2013 | US20130209564 Polysaccharide Particle Vaccines |
| 08/15/2013 | US20130209518 Combinations and modes of administration of therapeutic agents and combination therapy |
| 08/15/2013 | US20130209514 Aptamer-targeted costimulatory ligand aptamer |
| 08/15/2013 | US20130209510 Methods for preparing squalene |
| 08/15/2013 | US20130209509 H3 equine influenza a virus |
| 08/15/2013 | US20130209508 Compositions Containing Purine and Pyrimidine Nucleotsides, Peptides, and Manganese and Their Uses |
| 08/15/2013 | US20130209507 Rotavirus Subunit Vaccines and Methods of Making and Use Thereof |
| 08/15/2013 | US20130209506 Recombinant Virus with Diminished Latency and Methods of Using Same |
| 08/15/2013 | US20130209503 Method for stabilization of biological molecules |
| 08/15/2013 | US20130209501 Immunogenic Compositions of Staphylococcus Epidermidis Polypeptide Antigens |
| 08/15/2013 | US20130209498 Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease |
| 08/15/2013 | US20130209490 Diagnostic BioMarkers for Fibrotic Disorders |
| 08/15/2013 | US20130209488 Methods and compositions for malic enzyme 2 (me2) as a target for cancer therapy |
| 08/15/2013 | US20130209487 Treatment of Avian Species with Inhibitors of P110 Delta Signaling |
| 08/15/2013 | US20130209485 Therapeutic agent of non-allergic airway inflammation and/or non-allergic hyperresponsive airway |
| 08/15/2013 | US20130209484 Selective ampd2 inhibitors and methods for using the same |
| 08/15/2013 | US20130209480 Methods of treating rheumatoid arthritis using il-17 antagonists |
| 08/15/2013 | US20130209479 Cancer treatment |
| 08/15/2013 | US20130209477 Agents and method for treating inflammation-related conditions and diseases |
| 08/15/2013 | US20130209476 Treatment of inflammatory disorders |
| 08/15/2013 | US20130209475 Dkk1 antibodies and methods of use |
| 08/15/2013 | US20130209473 R-spondin translocations and methods using the same |
| 08/15/2013 | US20130209468 Use of MIF and MIF Pathway Agonists |
| 08/15/2013 | US20130209467 Method of treating fibroproliferative disorders |
| 08/15/2013 | US20130209465 Stabilized Aqueous Antibody Compositions |
| 08/15/2013 | US20130209464 Polypeptides having antiviral activity and methods for use thereof |
| 08/15/2013 | US20130209461 Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 08/15/2013 | US20130209459 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 08/15/2013 | US20130209456 Subtypes of humanized antibody against interleukin-6 receptor |
| 08/15/2013 | US20130209453 Use of tau to monitor immunotherapy |
| 08/15/2013 | US20130209451 Treatments for Cancer |
| 08/15/2013 | US20130209450 Compositions and Methods for Treating Glioblastoma GBM |
| 08/15/2013 | US20130209449 Anti-psgl-1 antibodies and uses thereof |
| 08/15/2013 | US20130209443 Method for Treating Oncological Diseases |
| 08/15/2013 | US20130209395 Nucleic acid molecule encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same |
| 08/15/2013 | US20130209394 Mn/ca ix and egfr pathway inhibition |
| 08/15/2013 | US20130209355 Antibodies against human cd38 |
| 08/15/2013 | CA2861051A1 Targeting of chondroitin sulfate glycans |
| 08/14/2013 | EP2626425A1 Influenza virus neutralizing antibody and method for screening same |
| 08/14/2013 | EP2626370A1 Immunogenic compositions containing Escherichia coli H7 flagella and methods of use thereof |
| 08/14/2013 | EP2626082A1 Method of preventing allergies |
| 08/14/2013 | EP2626081A1 Immunogenic control of tumours and tumour cells |
| 08/14/2013 | EP2626078A1 Inoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides |
| 08/14/2013 | EP2625204A1 Method to inhibit recruitment of monocytes and macrophages by an icam-3 inhibitor |
| 08/14/2013 | EP2625201A1 Cd33 binding agents |
| 08/14/2013 | EP2625199A1 Methods of treating psoriasis using il-17 antagonists |
| 08/14/2013 | EP2625198A2 Pharmaceutical composition |
| 08/14/2013 | EP2625195A2 Cancer targets |
| 08/14/2013 | EP2624868A2 A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
| 08/14/2013 | EP2624867A2 Methods for treating psoriasis |
| 08/14/2013 | EP2624866A2 Tumor specific antibodies and uses therefor |
| 08/14/2013 | EP2624865A1 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| 08/14/2013 | EP2624864A2 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 08/14/2013 | EP2624863A2 Probiotic therapies for autism |
| 08/14/2013 | EP2624862A1 Methods and compositions for inducing a t-cell response to plasmodium species |
| 08/14/2013 | EP2624861A1 Malaria vaccine |
| 08/14/2013 | EP2624858A1 Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours |
| 08/14/2013 | EP2624857A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases |
| 08/14/2013 | EP2624854A1 Moesin modulators and uses thereof |
| 08/14/2013 | EP2624852A1 Diagnostic and therapeutic uses of moesin fragments |
| 08/14/2013 | EP2624844A1 Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders |
| 08/14/2013 | EP2624815A1 Oral vaccine fast-dissolving dosage form using starch |
| 08/14/2013 | EP2624813A1 Composition for intraocular implantation of bevacizumab |
| 08/14/2013 | EP2149585B1 Use of antagonistic anti-CD40 monoclonal antibodies |
| 08/14/2013 | CN103249833A Human monoclonal antibody |
| 08/14/2013 | CN103249432A Antibodies to the c3d fragment of complement component 3 |
| 08/14/2013 | CN103249431A Mycobacterium antigenic composition |
| 08/14/2013 | CN103249430A Antigen-specific t cell receptors and t cell epitopes |
| 08/14/2013 | CN103243106A Epinephelus coioides interferon IFNgamma1 and preparation method and application thereof |
| 08/14/2013 | CN103242451A Multivalent immunoglobulin-based bioactive assemblies |
| 08/14/2013 | CN103242448A Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof |
| 08/14/2013 | CN103242447A Tweak binding antibodies |
| 08/14/2013 | CN103242434A Method for preparing acellular pertussis vaccine |
| 08/14/2013 | CN103242427A CTL epitope polypeptide of porcine reproductive and respiratory syndrome virus (PRRSV) and application thereof |
| 08/14/2013 | CN103242426A Avian influenza virus H5N1 subtype restrictive CTL epitope polypeptide and application thereof |
| 08/14/2013 | CN103239734A Vaccine for prevention and/or treatment of respiratory syncytial virus infection |
| 08/14/2013 | CN103239717A Replicon DNA (Deoxyribonucleic Acid) vaccine for treating chronic hepatitis B |
| 08/14/2013 | CN102718855B Anti-Pf 332-DBL sectional monoclonal antibody capable of inhibiting invasion of plasmodium falciparum |
| 08/14/2013 | CN102697812B Method for extracting exosome from chicken bile and application of exosome in immunology |
| 08/14/2013 | CN102671194B Human vaccine for preventing hydrophobia and tetanus |
| 08/14/2013 | CN102614527B Antiacid nano oral deoxyribonucleic acid (DNA) anti-tumor vaccine with potential of hydrogen (pH) sensitive characteristic and preparation method |
| 08/14/2013 | CN102586194B H9 subtype avian influenza virus Vero cell adapted strain and application thereof |
| 08/14/2013 | CN102533673B Chicken infectious bursal disease very virulent cell adapted strain and application thereof |
| 08/14/2013 | CN102344912B Porcine pseudorabies virus strain and porcine pseudorabies inactivated vaccine prepared by using same |
| 08/14/2013 | CN102327607B Production method of encephalitis B vaccine preparation |
| 08/14/2013 | CN102198268B Recombinant Swine pox virus (SPV) vector vaccine for the expression of Streptococcus equi subsp zooepidemicus (SEZ) M-like protein (SzP) |
| 08/14/2013 | CN102146137B Antibody to beta-amyloid peptide and application thereof |
| 08/14/2013 | CN101970500B Anti-tyrp1 antibodies |
| 08/14/2013 | CN101952320B Material with immunogenicity |
| 08/14/2013 | CN101942017B Tumor marker |
| 08/14/2013 | CN101869702B Vaccine produced by suspended microcarrier cell culture system and method for producing vaccine |
| 08/14/2013 | CN101700401B Polyalkylene glycol with moiety for conjugating biologicallyactive compound |
| 08/14/2013 | CN101654475B Antigenic epitope of human tumor necrosis factor alpha and preparation method and application thereof |
| 08/14/2013 | CN101646691B Anti-idiotype monoclonal antibodies as mimotopes of the HIV gp120 antigen |
| 08/14/2013 | CN101557822B Vaccin against group a beta hemolytic streptococcus and respective process for obtaining thereof |
| 08/14/2013 | CN101460194B Myxoma virus mutants for cancer treatment |
| 08/14/2013 | CN101420978B Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| 08/14/2013 | CN101346153B Immunoglobulin G (IGG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IGGS |
| 08/14/2013 | CN101325970B 抗cd40抗体的应用 Application of anti-cd40 antibody |